How semaglutide can affect your mood — and what the evidence says

What clinical trials and regulators have found about mood on semaglutide

The large phase-3 STEP 1 trial, published in the New England Journal of Medicine, followed nearly 2,000 adults with obesity over 68 weeks on semaglutide 2.4mg. Mood and psychological wellbeing were not primary endpoints, but quality-of-life measures improved significantly in the treatment group compared with placebo, a finding consistent with the broader picture that meaningful weight loss tends to carry a positive psychological dividend for many people.

That said, the semaglutide SmPC and the UK's NHS medicines page for semaglutide both list mood changes, depression and anxiety among side effects that patients and clinicians should be aware of. These are classified as uncommon rather than rare, meaning they appear in somewhere between 1 in 100 and 1 in 10 people across post-marketing data. The honest picture is therefore mixed: most people either notice no mood change or report feeling better; a smaller group experiences something more difficult, especially early in treatment.

Regulatory surveillance matters here. The MHRA continues to monitor semaglutide's safety profile through the Yellow Card system, and the European medicines data that informed UK licensing included review of suicidal ideation signals. Current UK guidance does not establish a confirmed causal link, but prescribers are asked to monitor patients and take reports seriously. This is precisely why same-day clinical review by a qualified prescriber (not an automated system) is part of responsible prescribing practice.

Why mood might shift in the first weeks of treatment

Several mechanisms may explain why some people notice mood changes early on, and distinguishing between them matters practically.

First, nausea and disrupted eating patterns are common in the dose-escalation phase. Feeling consistently unwell affects energy, sleep and emotional resilience. For some people, what reads as low mood is partly a GI side effect travelling upstream, it often settles as the body adjusts. Reading more about the full semaglutide side-effect profile can help put individual symptoms in context.

Second, significant dietary change and calorie reduction can themselves affect mood, particularly if protein or micronutrient intake falls short. A prescriber or dietitian can advise on maintaining nutritional adequacy while appetite is suppressed.

Third, GLP-1 receptors are found not only in the gut but in areas of the brain involved in appetite regulation and reward. Whether semaglutide's central action meaningfully influences mood pathways in humans is still an active area of research, and our page on Wegovy and mood explores what the current evidence does and does not show in more detail.

What this means practically: if you notice a mood shift in the first two to four weeks, log it, discuss it with your clinical team at the next review, and do not simply push through if it is affecting daily life. Some people find it helpful to keep a short daily note (even a line in the same app where you log your weekly dose reminder) so the pattern is visible when you speak to a prescriber. If symptoms are severe or include thoughts of self-harm, seek help the same day.

When mood changes need prompt medical attention

Most mood fluctuations on semaglutide are mild, transient and manageable with good clinical oversight. But the Wegovy side-effect guidance is clear that certain presentations require urgent action rather than watchful waiting.

Contact your GP or 111 promptly if you experience: persistent low mood lasting more than a few days; thoughts of harming yourself or others; sudden, marked changes in behaviour or personality; or significant anxiety that is interfering with daily function. These are not expected features of standard treatment and should not be attributed to the medicine without clinical input.

You can also report any suspected side effect directly to the MHRA via the Yellow Card scheme. This is open to patients as well as healthcare professionals, and the data genuinely feeds into the ongoing safety monitoring that shapes future prescribing guidance. It takes around ten minutes and is one of the most direct ways an individual can contribute to broader medicine safety.

If you are unsure whether what you are experiencing is linked to your treatment, our clinical support team is available seven days a week, this is the kind of question that deserves a real answer from a real person, not guesswork.

Mood, weight loss, and the longer-term picture

It is worth holding two things at once: semaglutide can, in a minority of people, contribute to low mood, and sustained weight loss is associated, in the majority of people, with improvements in depression scores, self-esteem and energy. Both are true, and neither cancels the other out.

For people with a history of depression, anxiety or eating disorders, starting a weight-loss medicine requires a particularly careful clinical conversation. A prescriber needs to know this history, not to exclude you automatically, but to plan appropriate monitoring and support. If you are also dealing with nausea or other physical symptoms alongside mood concerns, it is worth reading about feeling sick on semaglutide, since the two can sometimes be connected and managing one may help with the other. The broader question of how semaglutide affects mood over time is one our prescribers consider as part of every assessment, and it is part of the reason ongoing review matters as much as the initial consultation.

Treatment decisions are made by a GPhC-registered prescriber reviewing your individual circumstances. Explore your options and check your eligibility by visiting our weight-loss treatments page, where you can start a free consultation. Our clinical team takes these questions seriously, because they are serious. You can also find a full breakdown of what to expect on our page covering each side effect of semaglutide, which covers both physical and psychological effects reported by patients.